This document is a USPTO patent application (US20260083836A1) filed on June 15, 2023, titled 'Modified coronavirus spike antigen protein and uses thereof.' The application details a modified spike antigen protein that aims to improve safety by altering two cleavage sites, thereby suppressing cell membrane fusion ability. It also claims that vaccines incorporating this antigen protein can induce a high number of neutralizing antibodies, inhibiting viral invasion and proliferation.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in vaccine development, particularly those working on coronavirus-related therapeutics. Compliance officers in these sectors should be aware of emerging intellectual property in this area, which could impact future product development and market exclusivity.